This study compared two bedside methods recommended for the detection of low concentrations of heparin and the activated partial thromboplastin time (APTT), with reference to a laboratory measure of heparin concentration. Patients undergoing cardiopulmonary bypass had blood drawn at four stages when low levels of heparin could be expected. At each stage four tests were performed: whole blood clotting time using a Hemochron analyser with a Saline-Rinsed test cartridge, whole blood clotting time using a Hemotec analyser with a High Range Heparinase test cartridge, APTT, and heparin concentration by polybrene neutralization.
Abnormal bleeding may occur after cardiopulmonary bypass and lead to significant morbidity and exposure to blood products. Complete reversal of heparin in the post-bypass phase is essential. The high doses of heparin given for cardiopulmonary bypass are cleared from the circulation at varying rates, leading to uncertainty in the correct dose of protamine necessary for complete reversal 1 . Even if sufficient protamine is given to completely neutralize all heparin in the circulation, heparin rebound may occur in the hours after cardiopulmonary bypass.
A rapid bedside method of detecting low levels of heparin would answer a commonly asked question in cardiothoracic operating theatres: "does the patient need more protamine?". The activated whole blood clotting time has been used for this purpose but is insensitive and unreliable 2 . It has been suggested that modifications of the whole blood clotting time may improve the detection of low levels of heparin 3, 4 . Two such modifications are the Hemochron Saline-Rinsed whole blood clotting time, and the Hemotec High Range Heparinase cartridge.
The Hemochron Saline-Rinsed whole blood clotting time uses a glass test-tube containing a small metal rod which is placed in a thermostatically controlled rotating well. An electromagnetic detector determines when adhesion of the rod to the wall of the test tube occurs. The test-tube does not contain any activators, therefore clot formation takes longer than in the presence of an activator. The Hemotec High Range Heparinase cartridge has two reaction channels maintained at 37°C, both containing kaolin activator. One of the channels also contains enough bacterial heparinase to neutralise 6 U/ml of heparin. Clot formation is detected by repeatedly raising and releasing a small plunger out of the blood and timing its rate of fall through two optical beams. Blood is added to both channels, and the clotting time is determined independently for both channels. The presence of heparin will prolong the non-heparinasecontaining channel, and the difference (the heparinase-nonheparinase difference) will be dependent on the amount of heparin present in the sample.
The aim of this study was to investigate the performance of these bedside tests in cardiothoracic surgery patients with low concentrations of heparin, such as after subcutaneous injection or recently stopped IV infusions, and after partial and complete reversal of heparin with protamine.
METHOD
Human rights committee approval was obtained for the study, and patients participated with informed consent. Patients scheduled to undergo cardiopulmonary bypass for cardiac surgery were included in the trial. Patients with pre-existing coagulopathies or those on warfarin therapy were excluded.
All patients received preoperative heparin, either as therapy for unstable angina or as prophylaxis against venous thromboembolism. Those patients who were receiving intravenous heparin had the infusion stopped four hours prior to the anticipated time of surgery; other patients received 5000 units of subcutaneous heparin at 0600h on the morning of surgery.
Patients were premedicated with (per 70 kg) lorazepam 2 mg orally and an intramuscular injection of 10 mg of morphine and 50 mg of promethazine. Anaesthesia was induced with fentanyl 15-25 µg/kg and maintained with enflurane. Prior to cardiopulmonary bypass patients received 400 U/kg of porcine heparin sulphate (Delta West Pty Ltd) IV. During cardiopulmonary bypass additional heparin was given to maintain the activated clotting time, as measured by a kaolin-activated Hemochron cartridge (FKT-ACT, International Technidyne Corp., Edison, NJ), above 480s. Patients who had recently taken aspirin received 0.5 x 10 6 Kallikrien Inhibitor Units of aprotinin IV.
Cardiopulmonary bypass (CPB) was achieved with roller pump and a Capiox E membrane oxygenator, primed with 2.3 l of Plasmalyte 148 and 10,000U of heparin sulphate.
Protamine was administered after removal of the perfusion cannulae according to the schedule described below, to a total dose of 0.013 mg/unit of heparin dose.
All blood samples were taken from an arterial line which was kept patent by a continuous flush of unheparinized saline; four times the deadspace volume was withdrawn and discarded prior to collection of each sample. Blood samples were taken at four stages:
1. After the start of surgery, but before the administration of heparin for CPB.
2. After the administration of 1 mg/kg of protamine following discontinuation of CPB. 3. After a further 1 mg/kg of protamine. 4. On arrival in intensive care, after the administration of blood drained from the cardiopulmonary bypass equipment. At each sampling period the following tests were performed: (a) whole blood clotting time was measured using 2.5 ml of blood inserted into a Saline Rinsed Hemochron cartridge (S412 test tube, International Technidyne Corp., NJ), (b) whole blood clotting time was measured using 0.4 ml of blood added to both channels of a prewarmed High Range Heparinase cartridge (Medtronic Hemotec, Englewood CO), and citrated blood was sent to the laboratory for estimation of (c) Activated Partial Thromboplastin Time (APTT) and (d) heparin concentration by polybrene neutralization.
Activated Partial Thromboplastin Times were measured using Actin F.S.L. reagents in an A.C.L. automated device (Instrument Labs, I.L., Italy). Polybrene neutralization was performed according to the technique described by Grann et al 5 . Polybrene titrations were standardized according to an in vitro heparin titration to detect the following concentrations of heparin (U/ml): 0, 0.03, 0.1, 0.2, 0.6, 1.0, 2.0, 4.0.
Polybrene neutralization was used as the reference test for the presence of heparin. The lowest concentration of heparin detected by the polybrene titration was 0.03 U/ml: any concentration greater than this was considered to indicate the presence of heparin. The sensitivity and specificity of the Hemochron, Hemotec, and APTT was determined in relation to the manufacturer or laboratory normal ranges. Results higher than the normal range were considered a positive result, for that method, for the presence of heparin. The sensitivity of each method was calculated as number of positive/number of positive results by polybrene titration. The specificity of a method was calculated as number of negative results/number of negative results by polybrene titration. Our intention was to investigate the detection of low levels, and therefore samples with heparin concentrations greater than 1 U/ml were excluded from the analysis of sensitivity and specificity.
Receiver operating curves were constructed by calculating 1-specificity and sensitivity at each possible cut-off level for the test. Results were displayed graphically. The ideal receiver operating curve, indicating a test without false positives or false negatives, would begin at the origin, travel up the Y axis to a sensitivity of 1 and then travel in a horizontal line across the graph. A test producing results by chance would be expected to produce a straight line connecting the points with the x,y coordinates of 0,0 and 1,1.
Because results for all the clotting tests were skewed, the median and 95th centile range were used to describe central tendency and dispersion. Confidence intervals for proportional data were calculated according to the method described by Gardner and Altman 6 .
RESULTS
Thirty patients were studied. Four patients underwent surgery for valve disease, and 26 underwent surgery for coronary artery grafting. The mean age was 62 years and mean weight 82 kg. The mean duration of cardiopulmonary bypass was 84 minutes and the mean dose of heparin given (including that in the cardiopulmonary bypass prime) was 520 U/kg. Table 1 describes the results of coagulation test before surgery and on arrival in intensive care.
Three patients had been treated with a heparin infusion, which in each case was discontinued four hours prior to anaesthesia; the remaining patients received 6000 units of subcutaneous heparin a mean of four hours prior to the first sample of blood. Twenty-one patients had received low dose aspirin within ten days of surgery. No patient had been treated with dipyridamole. Table 2 shows the median heparin concentration at each stage of data collection.
For samples without polybrene-detectable heparin the median (and 95th centile range) for the APTT was 28 (18 to 41)s, for the Saline-Rinsed Hemochron 234 (175 to 345)s , and for the Hemotec heparinasenonheparinase difference 0 (-17 to + 13)s. For comparison our laboratory range of normal for the APTT is 18 to 26s, and the manufacturer's normal range for the Hemochron is 186 to 306s, and for the Hemotec heparinase-nonheparinase difference -10 to +10s. The median (and 95th centile range) of the Hemotec heparinase channel was 138 (109 to 179)s in samples without polybrene-detectable heparin, and 136 (110 to 175)s in samples with detectable heparin, which suggests that adequate neutralization of heparin occurred. Table 3 describes the sensitivity and specificity of the APTT, Saline-Rinsed Hemochron time, and the Hemotec heparinase-nonheparinase difference, for the detection of heparin activity in samples contain- ing less than 1 U/ml of heparin (102 samples), using polybrene neutralization as a reference. Figure 1 shows receiver operating curves for the APTT, Saline-Rinsed Hemochron, and the Hemotec heparinase-nonheparinase difference.
DISCUSSION
The results indicate that both the Hemochron and Hemotec devices have low sensitivity and relatively high specificities for the detection of low concentrations of heparin. For each device more than half the samples actually containing heparin gave negative test results, and approximately 10% of samples not containing heparin gave positive test results. This suggests that the Hemochron and Hemotec devices tend to give negative results of the presence of heparin. In contrast the APTT had a higher sensitivity but lower specificity than the Hemochron and Hemotec and would therefore tend to test positive regardless of the presence of heparin.
We have described the sensitivity and specificity of the bedside tests using the manufacturer's upper limit of normal to identify heparin containing samples. Could improvements be made by using a different cut-off? The receiver-operating curve charts the sensitivity and specificity of all possible cut-off levels of each test. Examination of the curves for the Hemochron and Hemotec do not suggest a significant improvement could be made with a different cut-off point. Examination of the curve for the APTT suggests it may offer superior discrimination between heparin-containing and non-heparin-containing than either the Hemochron or Hemotec tests.
Most, but not all, of our patients received ultra low dose aprotinin before cardiopulmonary bypass. Aprotinin is known to have an effect on celiteactivated clotting times 7 , but not on kaolin activated clotting times 8 . Therefore the use of aprotinin is unlikely to have influenced the results. We do not know if aprotinin affects the action of heparinase, but our findings of a constant heparinase channel clotting time regardless of the presence of heparin would suggest that it was not a significant effect in our study.
Post-bypass bleeding can be caused by many factors, including haemodilution, platelet activation, platelet deficiency, activation of fibrinolysis, hypothermia, and incomplete surgical haemostasis. The precise contribution of low concentrations of heparin is unclear, although it is possible that low concentrations of heparin have a synergistic effect upon the coagulopathy induced by cardiopulmonary bypass. Concentrations of heparin below 0.1 U/ml have been described in patients experiencing heparin rebound following CPB and were associated with increased blood loss 9 . Also, a recent paper has shown in vitro thromboelastographic abnormalities of blood with 0.07 U/ml of heparin 10 .
The median concentration of heparin after the administration of 2 mg/kg of protamine in this study was very low. It has been noted elsewhere that small doses of protamine will acutely reverse heparin after cardiopulmonary bypass 11 . Following the sample collection for this stage we gave further protamine to a total of approximately 6.5 mg/kg. In spite of this low levels of heparin were still detected in five patients on arrival in ICU. Clearly, further studies of the ideal regimen for protamine administration using sensitive and specific tests to detect low levels of free heparin are still required.
Although laboratory methods can offer accurate measures of heparin concentration, their usefulness is limited by the inherent delay before results are obtained. However, there are bedside monitors of heparin activity, particularly the Hepcon system 1 , or the heparinase modified thromboelastograph 12 , which may prove to have sufficient sensitivity and specificity for the adequate detection of low levels of heparin.
In conclusion the Hemotec Heparinase High Range cartridge and the Hemochron Saline-Rinsed cartridge have low sensitivity for the detection of low concentrations of heparin in cardiopulmonary bypass patients and should not be used for this purpose.
The APTT is more sensitive but less specific than either of these tests. We recommend that laboratory estimation of heparin concentration be performed if there is any doubt about the presence of heparin.
